Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
doi: 10.3389/fphys.2022.954948 Received 27 May 2022 Accepted 28 July 2022 Published 25 August 2022 Volume 13 - 2022 Edited by Robert Roghair, The University of Iowa, United States Reviewed by Jeffrey Segar, Medical College of Wisconsin, United States Michael Satterfield, Texas A&M University, United States Updates Copyright 2022 Stremming, White, Donthi, Batt, Hetrick, Chang, Wesolowski, Seefeldt, McCurdy, Rozance and Brown
Many commercial insurance plans cover GLP-1 medications for weight management, though coverage varies by payer and plan
:max_bytes(150000):strip_icc()/VWH-GettyImages-1692436619-6afbd0305e5e42359effc8b3deda6818.jpg)
Endocrinology 162 , bqab065 (2021)
US$ 24.08
US$ 28.26
US$ 25.78
